secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041358
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q2 net loss $15.8M; expects Phase 2 enrollment completion and Phase 3 start in Sep 2023
--------------------------------------------------------------------------------

- Net loss $15.8M for Q2 2023 vs $10.1M prior year; R&D expenses increased on clinical trial costs.
- Cash, cash equivalents and investments $95.3M at June 30, 2023, after ATM offering of 2.5M shares at $8.00.
- Phase 2 portion of pivotal epetraborole study for treatment-refractory MAC lung disease enrollment to finish in August; Phase 3 begins September.
- Top-line Phase 2 data expected summer 2024; over 90 active clinical sites across U.S., Japan, South Korea, Australia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023041358/0000950170-23-041358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023041358/antx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer